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a b s t r a c t
Objective: To investigate the clinical features, management, and prognosis of pulmonary
cryptococcosis in non-acquired immunodeﬁciency syndrome (AIDS) patients.
Method: 24 cases of pulmonary cryptococcosis with accurate pathological diagnosis were
retrospectively studied.
Results: 15 male patients and nine female patients were diagnosed at the ﬁrst afﬁliated
hospital of Sun Yat-sen University from November 1999 to November 2011. The mean age at
the time of diagnosis was 44.2± 11.3 years (range: 24 to 65 years). Among these patients, 13
had other comorbidities. 15 were symptomatic and the other nine were asymptomatic. The
most common presenting symptoms were cough, chest tightness, expectoration, and fever.
None had concurrent cryptococcal meningitis. The most frequent radiologic abnormalities
on chest computed tomography (CT) scanswere solitary ormultiple pulmonarynodules, and
masses or consolidations, and most lesions were located in the lower lobes. All patients had
biopsies for the accurate diagnosis. Among the 24 patients, nine patients underwent surgical
resections (eight had pneumonectomy via thoracotomy and one had a pneumonectomy via
thoracoscopy). Five of the patients who underwent surgery also received antifungal drug
therapy (ﬂuconazole) for one to three months after the surgery. The other 15 only received
antifungal drug therapy (ﬂuconazole or voriconazole) for three to six months (ﬁve patients
are still on therapy). The follow-up observation of 19 patients who had already ﬁnished their
treatments lasted from two to 11 years, and there was no relapse, dissemination, or deathin any of these patients.
Conclusion: Non-AIDS patients with pulmonary cryptococcosis have a good prognosis with
appropriate management.
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(AIDS) patients by retrospective analysis of 24 patients admit-
ted to this hospital from November 1999 to November 2011.
The study was approved by the institutional review board.
The requirement for a signed informed consent form was
waived by the institutional review board due to the retrospec-
tive nature of the study.
Material and methods
Study patients
This study included15malepatients andnine femalepatients,
who were both admitted and diagnosed in the ﬁrst afﬁliated
hospital of Sun Yat-sen University from November 1999 to
November 2011. The diagnoses were conﬁrmed by positive
pathology.
Data collection
All the clinical features, treatments, and prognoses of these
patients were retrospectively analysed based upon their med-
ical records. Patients without complete, detailed medical
records were excluded from this study.
Results
Gender and age
Among these 24 patients, there were 15 male and nine female.
Their ages ranged from 24 to 65 years, and the mean (± SD)
age at the time of diagnosis was 44.2 (± 11.3) years.
Occupation and epidemiological histories
Five patients were exposed to poultry (including pigeons,
turtle doves, and their feces). Four had close contact
with soil (three patients were peasants and one was
a geologist), and two worked in a hospital (No. 8 was
a nurse while her son No. 22 worked in the clinical
microbiology laboratory of the hospital). The remain-
ing 13 patients had no speciﬁc epidemiological expo-
sures.
Pre-existing conditions and immune competence
Patients’ pre-existing conditions are summarized in Table 1.
Of the 24 patients, 13 (54.2%) had comorbidities as fol-
lows: chronic viral hepatitis B (four patients, 16.7%), chronic
kidney disease (four patients, 16.7%), pulmonary tubercu-
losis (two patients, 8.3%), diabetes mellitus (two patients,
8.3%), hypertension (one patient, 4.2%), coronary heart dis-
ease (one patient, 4.2%), hyperthyroidism (two patients, 8.3%),
thyroid carcinoma (one patient, 4.2%), or myasthenia gravis
with thymoma (one patient, 4.2%); three patients had two
or more comorbidities. All patients were HIV-negative by
serologic tests, and none was organ transplant recipient.
However, ﬁve (20.8%) of these patients were immuno-
compromised; four had taken corticosteroids for over six12;16(6):531–539
months, and one had received chemotherapy for malig-
nancy.
Symptoms and signs
None of these patients had concurrent cryptococcal menin-
gitis based on the absence of meningeal irritation signs and
symptoms of intracranial hypertension. 15 patients (62.5%)
were symptomatic, including cough (nine patients, 37.5%),
chest tightness (eight patients, 33.3%), expectoration (six
patients, 25.0%), and fever (six patients, 25.0%, body tempera-
ture ranged from 37.7 ◦C to 39.4 ◦C). Nine patients (37.5%) were
totally asymptomatic. Among them, six had abnormalities on
chest X-ray during routine check-ups, and the remaining three
had some noted changes on their chest X-rays during the
treatment of other diseases. All asymptomatic patients were
immunocompetent. Ten of the 19 individuals with immuno-
competent were symptomatic (52.6%), and all ﬁve (100%)
immunocompromised patients were symptomatic. Physi-
cal examinations revealed diminished respiratory sounds
in only three patients. All patients had pulmonary cryp-
tococcosis without any extrapulmonary involvement, and
no progressive dissemination occurred during the follow-up
period.
Laboratory investigations
Elevations of the peripheral white blood cell count (WBC)
(10.22× 109/L-12.69× 109/L) were detected in four patients
(16.7%), while WBC counts of the other 20 patients were
within normal range. Sputum culture was performed in ten
cases, and two were positive for Cryptococcus neoformans. The
serum latex agglutination (LA) test, which detects crypto-
coccal capsule polyglycan antigens, was performed in 12
cases; 11 of them had positive results. The serum fun-
gal (1→3) -D-glucan test (G test) was performed in 12
cases, and weakly positive results were reported in two of
them.
Radiological characteristics
Computed tomography (CT) was performed in all patients
(Fig. 1), and the characteristics of the images are listed in
Table 2. Round or oval opacities < 3 cm in diameter were
considered as nodules. Masses were deﬁned as opacities
≥ 3 cm in diameter. The most common radiographic ﬁnd-
ings were multiple nodules and/or masses, solitary nodule
or mass, and consolidations, which could be seen in 58.3%,
25.0%, and 25.0% of patients, respectively. These nodules and
masses were distributed mostly in the periphery of the lung
ﬁeld and adjacent to the pleura. The margins of the lesions
were mostly poorly deﬁned, while lobulations and few short
spikes could be observed in most of the cases. The inte-
rior densities of nodules and masses were regular. Pleural
thickening and adhesions were present in most of the cases.
Concerning the distribution of the lesions, 15 patients (62.5%)
had only lower lobe involvement, eight patients (33.3%) had
both upper and lower lobe involvement (most lesions were
in lower lobes), and only one patient (4.2%) had only left






















Table 1 – Clinical data of patients with pulmonary cryptococcosis.
Patient No. Age,
years
Gender PCH/SCH Host status Immunocompromised
host
Symptoms Original diagnosis CT scans Treatments Follow-up
period,
years






RLL solitary nodule Thoracotomy pneumonectomy
and oral ﬂuconazole 150 mg per
day for two months after operation
11










Fluconazole 200 mg IV per day for
two months
10
3 45 F SCH Normal No Asymptomatic Pulmonary
carcinoma
LLL multiple nodules Thoracotomy pneumonectomy
and oral ﬂuconazole 150 mg per
day for one month after operation
6
4 31 F NO IgA nephropathy Yes Chest tightness, cough Pulmonary
carcinoma
LLL solitary nodule Thoracotomy pneumonectomy
and oral ﬂuconazole 150 mg per
day for two months after operation
6
5 40 M PCH Normal No Asymptomatic Pneumonia Left lung multiple
nodules
Thoracotomy pneumonectomy 6
6 34 M NO Normal No Cough, expectoration Pulmonary
tuberculosis
LLL solitary nodule
with halo sign and
consolidations
Thoracotomy pneumonectomy 5




Voriconazole 200 mg IV twice a day
for four weeks and oral 200 mg
twice a day for eight weeks
5





Voriconazole 200 mg IV twice a day
for four weeks and oral 200 mg
twice a day for four weeks
5





Yes Fever, chest tightness Pneumonia LUL solitary nodule
with pleural
effusions
Oral ﬂuconazole 300 mg per day
for two months
4





11 30 M NO Chronic viral
hepatitis B





Fluconazole 400 mg IV per day for
one month and oral 300 mg per
day for three months
4







and ﬂuconazole 400 mg IV per day
for one month, and then oral 300



























Gender PCH/SCH Host status Immunocompromised
host
Symptoms Original diagnosis CT scans Treatments Follow-up
period,
years












and oral ﬂuconazole 150 mg twice
a day for one month after
operation
3




Fluconazole 200 mg IV twice a day
for two months, and then oral 150
mg twice a day for four months
3





Voriconazole 200 mg IV twice a day
for two months, and then oral
ﬂuconazole 300 mg per day for one
month
3




RLL solitary nodule Thoracotomy pneumonectomy 3
17 58 M NO Myasthenia
gravis with
thymoma






Voriconazole 200 mg IV twice a day
for one month, and then oral
ﬂuconazole 150 mg twice a day for
three months
3









Oral voriconazole 200 mg twice a
day for eight weeks
3








Fluconazole 400 mg IV per day for
four months
2




RLL mass with halo
sign
Fluconazole 400 mg IV per day for




21 45 M PCH Normal No Asymptomatic Pneumonia Bilateral multiple
nodules
Fluconazole 600 mg IV per day for
14 days, 400 mg IV per day for ten
days, and then oral 450 mg per day
Ongoing
therapy




Fluconazole 600 mg IV per day for
six days, 400 mg IV per day for











Fluconazole 600 mg IV per day for




24 42 M NO Hyperthyroidism No Cough Pneumonia Bilateral masses Fluconazole 800 mg IV per day for




PCH, poultry contact history; SCH, soil contact history; RLL, right lower lobe; LUL, left upper lobe; LLL, left lower lobe.
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Fig. 1 – Chest CT images of pulmonary cryptococcosis. CT1
(patient No. 13) showing a mass with lobulation, short
spikes and focal pleural adhesion and thickening in right
lower lobe. CT2 (patient No.13, different scan levels of CT1)
showing multiple nodules of variable sizes in right lung
beneath the pleura. CT3 (patient No. 16) showing a solitary
nodule with short spikes and pleural stretching in
antero-basal section of the right lung. CT4 (patient No. 11)
showing patchy consolidations in the dorsal lower lobes of
bilateral lungs that were vaguely circumscribed and
adjacent to the pleura. CT5 (patient No. 20) showing a mass
with halo sign. CT6 obtained at the same level as CT5
showing lesion shrunk signiﬁcantly after administering
ﬂuconazole for three months. CT7 (patient No. 22) showing
multiple nodules in right lower lobe. CT8 obtained at the







Table 2 – Radiological characteristics of pulmonary
cryptococcosis.
Radiological characteristics No. (%)
Abnormality
Solitary nodule or mass 6 (25.0)
Multiple nodules and masses 14 (58.3)
Consolidations 6 (25.0)
With cavitations 1 (4.2)
With pleural effusions 1 (4.2)
With mediastinal and axillary lymph nodes
enlargement
1 (4.2)
With halo sign 2 (8.3)
Location (lung lesions)
Lower lobes 15 (62.5)
Left lower lobe 3 (12.5)
Right lower lobe 6 (25.0)
Bilateral lower lobes 6 (25.0)
Upper lobes 1 (4.2)
Left upper lobe 1 (4.2)
Lower lobes and upper lobes 8 (33.3)
Left lung 2 (8.3)
Right lung 3 (12.5)pplying ﬂuconazole for one month.
alo sign (two patients), and enlargement of mediastinal and
xillary lymph nodes (one patient) were observed in four of
9 immunocompetent patients, while small bilateral pleural
ffusions were observed in one of ﬁve immunocompromised
atients.Bilateral lungs 2 (8.3)
Diagnosis
Prior to pathological examinations, 20 patients (83.3%) were
misdiagnosed with other pulmonary conditions, including
lung cancer in seven cases, pulmonary tuberculosis in six
cases, pneumonia in ﬁve cases, and pulmonary metastases
in two cases. Diagnosis of pulmonary cryptococcosis in all
the 24 patients was ﬁnally conﬁrmed by pathological evidence
(Fig. 2). Percutaneous lung biopsy specimens were obtained in
nine cases (eight guidedbyCTandone guidedbyultrasonogra-
phy), thoracoscopic biopsies were obtained in seven cases (six
medical thoracoscopy biopsies and one surgical thoracoscopy
excision), and thoracotomy biopsies in eight cases. Cryptococ-
cal granulomas were present in all nine of the intraoperative
frozen section examinations performed, and the possibility
of malignancy was ruled out. Round or oval vesicular crypto-
cocci were faintly stained and identiﬁable in the cytoplasm
of polynuclear giant cells. In the parafﬁn-embedded slides,
cryptococcal granulomas were found in 21 out of 24 cases.
Moreover, colloid lesions containing cryptococciwere revealed
in the pathological slides of the three other cases. Granu-
lomas were mainly composed of macrophages, polynuclear
giant cells, histiocytes, and ﬁbroblasts, as well as inﬁltrations
of lymphocytes and small amounts of neutrophils. Cells were
diffusely located within the lesions, and did not converge
into any evident nodules; round or oval vesicular crypto-
cocci were faintly visible in the cytoplasm of polynuclear
giant cells and macrophages, stroma of lesions, bronchioles,
and alveolar cavities. Colloid lesions mainly arose from piles
of cryptococcal spores and mucinous degenerated tissues.
Cysts circumscribed by ﬁbrous tissues were present in those
colloid tissues, while granulomatous reactions or inﬂamma-
tory inﬁltrationswere not observed. Regardinghistochemistry,
periodic acid Schiff (PAS) staining was positive in 21 cases
(21/22, 95.5%), while periodic acid-silver methenamine (PASM)
staining was positive in all 24 cases (24/24, 100%). Lung tissue
i s . 20536 braz j infect d
culture of cryptococcus was performed for patient No. 21, and
a positive result was reported.
Management and follow-up
All patients received treatment including surgery or antifungal
drug therapy. Eight of nine patients who underwent surgical
therapy received pneumonectomy via thoracotomy. Among
them, four took oral ﬂuconazole 150-300mg per day post-
operatively for one to two months, and the other four did
not take any antifungal drugs after surgery. The other one
patient received intravenous ﬂuconazole 400mg per day for
one month, and subsequent oral ﬂuconazole 300mg per day
for another two months. The 15 cases managed without pneu-
monectomywere given ﬂuconazole 200-800mgper day and/or
voriconazole 400mg per day for two to six months (Table 3).
Among these 24 patients, ﬁve are still on therapy. The other
19 patients underwent chest X-ray or CT scans during regular
follow-up visits, which lasted from two to 11 years. In follow-
up examinations, no relapse was observed in the nine cases
that received surgical treatment, while all the lesions in the
ten cases who completed drug therapy shrunk signiﬁcantly
and did not subsequently enlarge.
Discussion
As the clinical descriptions of pulmonary cryptococcosis in
non-AIDS individuals are quite limited, this study was per-
formed in order to better characterize this condition. In
general, males are more frequently infected than females,1
and in the present study the disease was also overwhelmingly
predominant in males. None of the individuals included in the
study was an AIDS patient or a transplant graft recipient. The
results indicated that cryptococcosis can occur in immuno-
competent patients, and compromised immunity, as well as
chronic diseases, are the major risk factors for this condition.
Approximately half of the cases studied had infections super-
imposed on pre-existing conditions, including compromised
immunity.
Although pulmonary cryptococcosis is generally an air-
borne disease, exposures to soil or poultry prior to onset are
rather common. It is noteworthy that patients No. 8 and No.
22 were mother and son who lived together, and the son
worked in the clinical microbiology laboratory of the hospi-
tal. Although the mother had no working experience in the
microbiology laboratory, living together may have created an
environment in which the mother might have been infected
by her son. The reason why the mother was diagnosed four
years earlier might be her lower immunity due to age.
Presentations of pulmonary cryptococcosis were non-
speciﬁc or even totally silent. In some recent studies,
approximately one-third of immunocompetent patients with
pulmonary cryptococcosis were asymptomatic.2,3 The present
study revealed an even higher proportion; half (9/19, 47.4%)
of immunocompetent patients with pulmonary cryptococco-
sis were asymptomatic, and their disease was incidentally
detected during routine chest X-ray check-ups or follow-up of
other diseases, while all immunocompromised patients were
symptomatic. Common symptoms included fever, cough,12;16(6):531–539
expectoration, chest tightness, chest pain, weight loss, night
sweats, and dyspnea.4–6 These symptoms can also be mani-
fested in other common diseases of the respiratory system,
including lung cancer, pneumonia, and pulmonary tuber-
culosis. Therefore, pulmonary cryptococcosis is likely to
be misdiagnosed. However, in comparison to non-AIDS
patients, AIDS patients with pulmonary cryptococcosis gen-
erally present with more severe symptoms or even global
dissemination, and infections may involve the central ner-
vous system, the skin and mucous membranes, or the bones
and joints.7–9 The most common site of dissemination is the
central nervous system, which can produce symptoms such
as headache, nausea, vomiting, convulsions, or even paraly-
sis and coma.9,10 These symptoms are not commonly seen in
non-AIDS patients.
Routine laboratory investigations, including peripheral
white blood cell counts, and erythrocyte sedimentation rate,
among others,were generally nonspeciﬁc in the present study,
which is consistent with a previous study.10 Regarding micro-
biology investigations, positive sputum culture result is very
important to the diagnosis, but is less sensitive than serum G
and LA tests. In this study, 11 of 12 patients had positive LA
tests at diagnosis, showing a very high sensitivity. Lin et al.7
found that LA test positivity rate had no statistical difference
between immunocompetent and immunocompromised indi-
viduals, but the titers were signiﬁcantly higher in HIV-infected
patients than in those without HIV. LA tests can become
negative in response to effective treatment and can remain
persistently positive in cases with ineffective treatment or
relapse.3,7,11 However, according to the practice guidelines for
the management of cryptococcal disease of the Infectious Dis-
ease Society of America (IDSA),12 the duration of anti-fungal
therapy for pulmonary cryptococcosis is not relevant to neg-
ative alterations of the cryptococcal antigen tests. Differing
from the LA test, the G test targets (1→3) -D-glycan, which
is a component of the fungal cell wall. In comparison to Can-
dida and Aspergilli, the cell wall of Cryptococcus contains less
(1→3) -D-glycan and is coated with a thick capsule, which
hinders the release of (1→3) -D-glycan into the circulation.7
Therefore, the results of the G test are usually negative or
occasionally weakly positive in pulmonary cryptococcosis.
However, after antifungal drug therapy, the thick capsule of
Cryptococcus is destroyed, and it releases signiﬁcantly more
(1→3) -D-glycan into the circulation, which could lead to pos-
itive G test results. Then, when the therapy is continued, the
growth of Cryptococcus is restrained, so the titer of (1→3) -D-
glycan decreases or turns negative. In the present study, only
two (patients No. 21 and No. 22) out of 12 patients had weakly
positive G test results at diagnosis. Four patients (patients No.
20 throught No. 23) who had their G test checked repeatedly
demonstrated signiﬁcant increase in their G test results after
antifungal therapy for 1-2 weeks, which turned negative after
about one month.
Radiological presentations of pulmonary cryptococcosis
are variable. Previous studies4–6 have shown that solitary or
multiple subpleural nodules or masses with/without halo sign
are common on CT scans in non-AIDS pulmonary cryptococ-
cosis. Consolidations and pleural effusions with occasional
mediastinal lymph node enlargement, although not common,
are found in some cases.6,13 Lesions are mainly located in
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Fig. 2 – Pathological features of pulmonary cryptococcosis. Microscopic examinations of the pulmonary tissues of two
patients (patients No. 10 and No. 13) revealed that large numbers of polynuclear giant cells were diffusely distributed;
ﬁbrosis of the stromal tissues and massive inﬂammatory inﬁltrations were shown. Round cryptococci were found in
alveolar cavities as well as the cytoplasm of polynuclear giant cells. These features conﬁrmed the diagnosis of cryptococcal





iells, which were in accordance with the characteristics of c
iddle and lower ﬁelds, or diffusely distributed throughout
he entire lung.13–15 The radiological ﬁndings in the present
tudy are consistent with the ﬁndings of these previous stud-
es. Some of the lesions appeared as multiple nodules, mainly
Table 3 – Treatments of patients with pulmonary cryptococcosi
Treatment
Thoracotomy pneumonectomy only
Thoracotomy pneumonectomy, followed by ﬂuconazole 150-300mg per da
months
Thoracoscopic pneumonectomy, followed by ﬂuconazole 400mg per day IV
300mg per day orally for two months
Fluconazole 200-400mg per day IV for one to four months, with (two cases
300mg per day orally for three to four months
Fluconazole 400-800mg per day IV for seven to 24 days and then 300-450m
therapy)
Fluconazole 300mg per day orally for two months
Voriconazole 400mg per day IV for one month and then 400mg per day or
Voriconazole 400mg per day IV for one to two months, and then oral ﬂuco
one to three monthscoccal infections.
located in close proximity to the pleura, generating confu-
sion with pulmonary tuberculosis. Others occurred as solitary
nodules, most of which had ill-deﬁned boundaries with lob-




y orally for one to two 4 (16.7)
for one month, and by 1 (4.2)
) or without (two cases) 4 (16.7)
g per day orally (still on 5 (20.8)
1 (4.2)
ally for one to two months 3 (12.5)
nazole 300mg per day for 2 (8.3)
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presumptively diagnose lung cancers.14,16,17 Therefore, if a
patient has a relatively slow progression of lesions, as well
as a poor response to antibiotics, with an absence of a sys-
temic inﬂammation response, tuberculosis septicemia, and
chronic consumptive manifestations caused by malignant
tumors, then pulmonary cryptococcosis should be carefully
considered. In contrast, the chest CT scans of AIDS patients
with pulmonary cryptococcosis showed diffusely distributed
or patchy shadows in the lungs.11,18 In cases with central
nervous system involvement, the cranial CT scans can also
reveal diffuse cerebral edema or patchy shadows of isodensity,
slightly elevated density, or low density.1
Lung tissue biopsies and pathological examinations are
the main methods to conﬁrm the diagnosis of pulmonary
cryptococcosis. In immunocompetent patients, the initial pre-
sentations of pulmonary cryptococcosis are fungi-containing
colloid lesions, which will gradually develop into granulo-
mas, manifested radiologically as solitary or multiple nodular
lesions in more advanced cases. Conversely, when immune
functions are impaired, pulmonary cryptococcosis is com-
monly found as fungi-containing colloid lesions, which tend
to disseminate within the lungs instead of becoming granulo-
mas, giving rise to diffuse multiple nodular shadows or patchy
consolidations on imaging scans.1,19,20 PAS and PASM/GMS
(Grocott’s methenamine silver) staining are commonly used
for cryptococcosis due to their high detection rates.1,19,20 In
the present study, the detection rates by PAS and PASM were
95.5% and 100%, respectively.
Management of pulmonary cryptococcosis depends on
the immune condition of the host, and on the existence of
extrapulmonary infections.10,12 The IDSA guideline of 201012
differentiates therapeutic protocols for patients of pulmonary
cryptococcosis in normal and impaired immune status. The
guideline recommends oral ﬂuconazole 400mg per day for
six to 12 months in immunocompetent patients; in patients
with persistent positive serum cryptococcal antigen detec-
tions, treatment could be withheld after therapy for six to 12
months. If the diagnosis is not conﬁrmed and radiological or
clinical presentations remain after regular anti-fungal thera-
pies, surgical resection should be considered. If the lesions are
not responsive to regular ﬂuconazole treatment or if admin-
istration of ﬂuconazole is contraindicated, oral itraconazole
(200mg twice a day), voriconazole (200mg twice a day) or
posaconazole (400mg twice a day) can serve as alternatives.
In immunocompromised patients, central nervous system
disease should be ruled out by lumbar puncture. For immuno-
compromised patients with mild to moderate symptoms,
negative results for dissemination, without diffuse inﬁltrates
in the lung, and without heavy immunosuppression, the anti-
fungal therapies are the same as those for immunocompetent
patients. In AIDS patients, for those who underwent HAART
(highly active antiretroviral therapy) and had CD4 counts
above 100/ul and in whom the titer of cryptococcal antigens
stopped increasing or fell below 1:512, ﬂuconazole can be
withheld after one year of therapy. Otherwise, lifelong oral
ﬂuconazole as maintenance is necessary to prevent relapse.
Among the 24 patients in this study, ﬁve are still under-
going treatments. The follow-up period in the remaining 19
patientswhohadﬁnished their treatments ranged from two to
11 years, and there was no relapse, dissemination, or death in12;16(6):531–539
any of these patients. Hence it can be concluded that early vig-
orous treatments can prevent cryptococcal meningitis caused
by dissemination of cryptococci, and therefore can improve
prognosis of pulmonary cryptococcosis.
Eight out of the nine patients in the present study who
underwent surgical therapy were immunocompetent. Among
them, four accepted antifungal drugs after the surgery, and
the other four did not. These eight patients were followed
up from three to 11 years, and no relapse was observed.
Thus, it can be inferred that antifungal drugs may not be
necessary for immunocompetent patients after their surgi-
cal therapy. Besides, there were ten patients in the present
study who received antifungal therapy for only two to six
months and had already ﬁnished treatment. Nine of these ten
(ﬁve immunocompetent and four immunocompromised)were
symptomatic and received only one to three months of anti-
fungal drugs after the symptomswere relieved. The remaining
patient, who was asymptomatic, underwent chest-X ray or
CT scans during follow-up visits, which showed that the lung
lesions diminished to some extent after one month of anti-
fungal therapy, but they had not completely disappeared even
after a six-month therapy completed, and did not enlarge or
diminish in the three years of follow-up examinations. In clin-
ical work, there were a comparable number of patients who
accepted antifungal therapy for various periods, and their lung
lesions did not fully disappear either. Thus, in order to choose
the appropriate time to stop therapy, in combination with the
present study’s ﬁndings, symptom relief should be taken into
consideration. For patients whose symptoms were relieved,
one to three months therapy after relief was preferred. For
asymptomatic patients, after the entire six months therapy, if
the lesions diminished or stopped growing and no new lesion
was found, antifungal therapy could be withdrawn.
The present study had some limitations. First, due to
the rarity of immunocompetent patients with pulmonary
cryptococcosis without cryptococcal meningitis, there were a
comparatively small number of cases included in the study,
which were selected over a long time. Second, all cases were
retrospectively studied, so not all patients in this study had
the LA test at the time of diagnosis, because the hospital had
not yet initiated the LA test, and furthermore, the dosage and
duration for each patient was not identical. However, with
further research and more knowledge about pulmonary cryp-
tococcosis as well as the publication of new guidelines, the
authors believe that diagnosis and management of this dis-
ease will be more accurate and effective.
In conclusion, diagnosis and treatment of pulmonary cryp-
tococcosis are still challenging. However, with early diagnosis
and appropriate management, most non-AIDS patients with
pulmonary cryptococcosis have a good prognosis.
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